The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Aug. 04, 2015

Filed:

Dec. 20, 2012
Applicant:

Alexion Cambridge Corporation, Cheshire, CT (US);

Inventors:

Woodruff Emlen, Greenwood Village, CO (US);

V. Michael Holers, Denver, CO (US);

Peter Flynn, San Francisco, CA (US);

Assignee:

Alexion Pharmaceuticals, Inc., Cheshire, CT (US);

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/00 (2006.01); A61K 39/395 (2006.01); C07K 16/00 (2006.01); C12P 21/08 (2006.01); C07K 16/40 (2006.01); C07K 16/18 (2006.01); C07K 16/46 (2006.01);
U.S. Cl.
CPC ...
C07K 16/40 (2013.01); C07K 16/18 (2013.01); C07K 16/461 (2013.01); A61K 2039/505 (2013.01); C07K 2317/55 (2013.01); C07K 2317/56 (2013.01); C07K 2317/92 (2013.01);
Abstract

This invention relates to humaneered anti-factor B antibodies and antigen-binding fragments thereof with reduced immunogenicity. The humaneered anti-factor B antibodies and antigen-binding fragments thereof are derived from murine monoclonal antibody 1379, which binds factor B in the third short consensus repeat ('SCR') domain and selectively inhibits activation of the alternative complement pathway by preventing formation of the C3bBb complex. The invention also relates to methods of treating diseases or disorders in which activation of the alternative complement pathway plays a role, and methods of selectively inhibiting activation of the alternative complement pathway in an individual in need thereof.


Find Patent Forward Citations

Loading…